ETHORGA

Ethorga is a French biotechnology company focused on developing first-in-class therapies for aggressive solid tumors by targeting the Ethorga pathway. A spin-off from the University of Bordeaux and INSERM, the company leverages its proprietary platform to inhibit the Ethorga protein, a key regulator of the tumor microenvironment and angiogenesis. Its lead program, ETH-101, is a monoclonal antibody designed to treat indications with high unmet needs, such as glioblastoma and pancreatic cancer. Ethorga aims to disrupt tumor growth and resistance mechanisms through its novel approach to immunotherapy and precision medicine. The company's research is based on decades of expertise in vascular biology and oncology from its founding scientific team.